ACLX
NASDAQArcellx Inc.
Price$115.05+46.20 (+67.10%)
2026-01-222026-04-27
News · 26 weeks73-100%
2025-12-142026-06-07
Mix3490d
- SEC Filings14(41%)
- Insider12(35%)
- Other7(21%)
- M&A1(3%)
Latest news
25 items- SECSEC Form 15-12G filed by Arcellx Inc.15-12G - Arcellx, Inc. (0001786205) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Arcellx Inc.SCHEDULE 13D/A - Arcellx, Inc. (0001786205) (Subject)
- INSIDERSEC Form 4 filed by Director Carroll Jill to satisfy tax liability4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERDirector Behbahani Ali closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERSEC Form 4 filed by Director Ware Olivia C4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERSEC Form 4 filed by Director Patel Kavita4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERSEC Form 4 filed by Director Myers Kristin4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERDirector Lubner David Charles closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERSEC Form 4 filed by Director Galligan Andrew H (tax withholding)4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Gilson Michelle closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Arcellx, Inc. (0001786205) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Heery Christopher closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Arcellx, Inc. (0001786205) (Issuer)
- SECSEC Form S-8 POS filed by Arcellx Inc.S-8 POS - Arcellx, Inc. (0001786205) (Filer)
- INSIDEROfficer Elghandour Rami closing all direct ownership in the company (SEC Form 4) (tax liability)4 - Arcellx, Inc. (0001786205) (Issuer)
- SECSEC Form S-8 POS filed by Arcellx Inc.S-8 POS - Arcellx, Inc. (0001786205) (Filer)
- SECSEC Form S-8 POS filed by Arcellx Inc.S-8 POS - Arcellx, Inc. (0001786205) (Filer)
- SECSEC Form S-8 POS filed by Arcellx Inc.S-8 POS - Arcellx, Inc. (0001786205) (Filer)
- SECSEC Form S-8 POS filed by Arcellx Inc.S-8 POS - Arcellx, Inc. (0001786205) (Filer)
- SECSEC Form POSASR filed by Arcellx Inc.POSASR - Arcellx, Inc. (0001786205) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Arcellx Inc.SCHEDULE 13D/A - Arcellx, Inc. (0001786205) (Subject)
- SECArcellx Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Arcellx, Inc. (0001786205) (Filer)
- SECSEC Form 25-NSE filed by Arcellx Inc.25-NSE - Arcellx, Inc. (0001786205) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Arcellx Inc.SCHEDULE 13D/A - Arcellx, Inc. (0001786205) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by Arcellx Inc.SC 14D9/A - Arcellx, Inc. (0001786205) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Arcellx Inc.SC TO-T/A - Arcellx, Inc. (0001786205) (Subject)
- PRGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celGilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim
ACLX FAQ
7 questionsWhat does Arcellx Inc. do?
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)...Where does ACLX stock trade?
Arcellx Inc. (ACLX) is listed on NASDAQ.What sector and industry is ACLX in?
Arcellx Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Arcellx Inc. go public?
Arcellx Inc. (ACLX) completed its IPO in 2022.What are analysts saying about ACLX?
Arcellx Inc. has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Neutral on 2026-02-12.What companies are similar to ACLX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ACLX side-by-side with any of them on Quantisnow.How can I track ACLX on Quantisnow?
Quantisnow aggregates Arcellx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACLX to receive live email and push alerts on every new disclosure.